+5.7%
HPQ vs MRNA
-27.3%
+33.0%
-51.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.5% | -2.2% | +2.7% | +0.6% |
| 7D | -4.8% | -12.7% | +7.9% | -4.2% |
| 30D | -10.7% | -20.7% | +9.9% | -10.0% |
| 3M | -4.2% | +46.3% | -50.5% | -6.7% |
| 6M | +35.6% | +305.2% | -269.6% | +16.0% |
| YTD | +30.3% | +561.2% | -530.9% | +1.9% |
| 1Y | +30.0% | +772.1% | -742.1% | -3.1% |
| 3Y | +13.0% | +147.0% | -133.9% | -3.4% |
| All | +5.7% | -27.3% | +33.0% | -4.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling